Pharma industry 'strategic crisis'


The pharma industry is grappling with a ‘strategic crisis’ according to three quarters of companies surveyed in a report from consultancy firm Roland Berger. The problem is shrinking margins, caused by price and cost pressure, regulatory change and expiring patents.

The top 10 pharma companies increased sales by 13% from 2009 to 2010, but their profits dropped during the same period by 4%. Compounding the problem in the long term, R&D costs have risen 80% over the past 10 years, while the number of new product launches has dropped by 43%.

Emerging markets offer the biggest growth – their market share is set to rise to 40% by 2016. The market for pharmaceutical products will grow on average by 4.5% annually until 2016. But growth in emerging markets will increase by almost 12%. China, Brazil, India and Russia (the so-called BRIC economies) in particular are experiencing high growth.

Half of the companies said they would be willing to move their administration, R&D and sales departments to emerging market regions.


Related Content

Weathering the storm

6 January 2014 Business

news image

Pharmaceutical industry roundup 2013

The hunt for innovation

31 January 2014 Premium contentFeature

news image

Big pharma companies are embracing a more open and collaborative approach. Nuala Moran discovers who’s working with whom

Most Read

Schott's glass

29 April 2015 Classic Kit

news image

Life through a lens

First pictures of hydrogen bonds unveiled

26 September 2013 Research

news image

Observation of intermolecular interactions in quinolines could help to settle the nature of this kind of bonding

Most Commented

Science for life: a manual for better living

1 May 2015 Review

news image

Looking beyond the hype

An unfortunate oversight

27 April 2015 Critical Point

news image

The US Toxic Substances Control Act is in dire need of reform. That demands compromises, says Mark Peplow